ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia

Conditions

• Asthma
• Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

ARES is a multi-centre, retrospective-prospective, non-comparative and non-interventional (observational) cohort study involving primary and secondary data collection within real-world settings of participants who have initiated tezepelumab (no more than 4 weeks before inclusion) for treatment of CRSwNP (with or without comorbid asthma).

Key Dates

First listed

Feb 10, 2026

Start date

Dec 25, 2025

Status verified

Jul 2026

Primary completion

Mar 31, 2028

Completion

Mar 31, 2028

Study Design

Enrollment

110 participants (estimated)

Primary Outcome Measure

1. Change in endoscopic status of CRSwNP based on NPS [ Time Frame: time points to measure: baseline and at Weeks 4, 24 and 52 following tezepelumab initiation ]

Central Contacts

• AstraZeneca Clinical Study Information Center
  1-877-240-9479
  [email protected]

Find similar trials

Related Studies

• Role of Genetic Factors in the Development of Lung Disease
  Recruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
• Personalized Environment and Genes Study
  Recruiting · National Institute of Environmental Health Sciences (NIEHS) · Chapel Hill, North Carolina
• Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
  Recruiting · Gelb, Arthur F., M.D. · Lakewood, California
• Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
  PHASE1 · Recruiting · Benjamin Medoff · Boston, Massachusetts